Effect of Essential Phospholipids in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomised Phase 4 Clinical Trial - PubMed

6 hours ago

Essential phospholipids (EPL) significantly reduced liver steatosis (measured by CAP score) in MASLD patients compared to placebo over 6 months, with effects evident from 3 months and sustained post-treatment.
EPL improved quality of life, particularly reducing fatigue, and significantly lowered HbA1c levels, indicating better glycemic control, with no safety concerns reported.
The study suggests EPL is a promising adjunctive therapy for managing steatosis and enhancing liver health in MASLD patients with cardiometabolic risks like diabetes, hyperlipidemia, or obesity.

Hasty Briefsbeta